Experience

Zevra Therapeutics

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Senior Director, CMC

  • Feb 2023 - Present

• Senior Director CMC

  • Dec 2022 - Present

• Director CMC

  • Jun 2013 - Present

• Senior Research Scientist

  • Jul 2009 - Jun 2013



New River Pharmaceutials

• Research Scientist

  • Mar 2005 - Jun 2007

  Design and synthesis of prodrugs of pharmaceutically active drugs. -Involved in synthesis and purification of solution phase small peptides. -Design and synthesize prodrugs of pharmaceutically active drugs by chemical modification of these drugs using metabolically-cleavable linkages. The goal is to improve the pharmacological properties of clinically useful antiviral agents and optimize their biological, clinical and market potential. -Involved in the design and synthesis of… Show more Design and synthesis of prodrugs of pharmaceutically active drugs. -Involved in synthesis and purification of solution phase small peptides. -Design and synthesize prodrugs of pharmaceutically active drugs by chemical modification of these drugs using metabolically-cleavable linkages. The goal is to improve the pharmacological properties of clinically useful antiviral agents and optimize their biological, clinical and market potential. -Involved in the design and synthesis of prodrugs of opioids (natural and synthetic) and identified lead candidates, based on non-clinical and physical data. -Involved in design and synthesis of prodrugs for hypothyroidism. -Involved in process development of a lead drug candidate (NRP-290) as a team member. Show less Design and synthesis of prodrugs of pharmaceutically active drugs. -Involved in synthesis and purification of solution phase small peptides. -Design and synthesize prodrugs of pharmaceutically active drugs by chemical modification of these drugs using metabolically-cleavable linkages. The goal is to improve the pharmacological properties of clinically useful antiviral agents and optimize their biological, clinical and market potential. -Involved in the design and synthesis of… Show more Design and synthesis of prodrugs of pharmaceutically active drugs. -Involved in synthesis and purification of solution phase small peptides. -Design and synthesize prodrugs of pharmaceutically active drugs by chemical modification of these drugs using metabolically-cleavable linkages. The goal is to improve the pharmacological properties of clinically useful antiviral agents and optimize their biological, clinical and market potential. -Involved in the design and synthesis of prodrugs of opioids (natural and synthetic) and identified lead candidates, based on non-clinical and physical data. -Involved in design and synthesis of prodrugs for hypothyroidism. -Involved in process development of a lead drug candidate (NRP-290) as a team member. Show less



University of Iowa

• United States
• Higher Education
• 700 & Above Employee

• Post Doc

  • Jan 2000 - Aug 2002

  Design and synthesis of modified nucleosides as potential anti-HIV agents. Design and synthesis of modified nucleosides as potential anti-HIV agents.